Alvotech (ALVO) Following Pipeline And Earnings Update, Is The Selloff A Bargain Or Priced In?
Alvotech (NasdaqGM:ALVO) reported a swing to a US$140.66 million net loss for the first nine months of 2026, alongside a fresh update on its biosimilar pipeline and manufacturing footprint.
The earnings miss and pipeline update landed in a weak tape for Alvotech, with the 1 day share price return down 10.28% and the 7 day move down 13.79%. The 90 day share price return is still up 3.33%, while the 1 year total shareholder return is down 23.68%. This suggests that short term momentum has cooled even as investors weigh longer term biosimilar approvals, capacity expansion and new partnerships.
Scan how Alvotech fits into the wider biosimilar and healthcare opportunity set by comparing it with 36 healthcare AI stocks that are already on investors' radar.
Alvotech now trades well below both analyst targets and some intrinsic value estimates after this drop. Is that discount compensating you for execution and regulatory risk, or simply reflecting it?
Most Popular Narrative: 42% Undervalued
Alvotech last closed at $4.19, while the analyst consensus Narrative on Simply Wall St pegs fair value at $7.20 per share using an 8.74% discount rate. That gap frames a thesis that leans heavily on future biosimilar launches and execution on the manufacturing ramp.
Upcoming first-wave and limited-competition biosimilar launches such as Simponi, Entyvio IV and SC, Eylea 2 mg and Eylea HD, Cimzia, Ilaris and Xolair are expected to open access to large reference markets where Alvotech targets meaningful share, which could support future revenue and earnings growth.
See why 14 investors see Alvotech as 42% undervalued.
Result: Fair Value of $7.20 (UNDERVALUED)
Still, the story around Alvotech only holds if manufacturing disruptions remain contained and the higher-cost debt and equity raises do not further erode shareholder value.
Find out about the key risks to this Alvotech narrative.
Next Steps
Mixed signals often create the best testing ground for your own process, so move quickly through the numbers, risks and upside, and then weigh the 3 key rewards and 2 important warning signs.
Looking for more ideas beyond Alvotech?
If you stop with just one ticker, you limit your options. Let the data surface fresh angles so you are not guessing where to look next.
- Target steadier compounding by scanning a diversified group of resilient companies through the 31 resilient stocks with low risk scores.
- Hunt for quality at a discount by checking which opportunities rise to the top in the 32 high quality undervalued stocks.
- Prioritize balance sheet strength by filtering for companies with healthier fundamentals using the list of solid balance sheet and fundamentals (24 results).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com